ANRO MEXC RealStocks
Own real ANRO shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 07:05:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Alto Neuroscience Inc. (ANRO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $30.60, with a market capitalization of $1.25B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $10.80 to $37.48. This page covers its latest market performance, valuation, price trends and company information.
$1.25B | |
$30.44 | |
$33.52 | |
$30.41 | |
$31.15 | |
1.20M | |
597.11K | |
-- | |
$37.48 | |
$10.80 | |
-- | |
-- |
Alto Neuroscience Inc. (ANRO) last closed at $30.60 as of 2026-11-13 00:45:00, down 1.70% ($0.53) from the previous close of $31.15.
During the latest regular trading session, ANRO traded between $30.41 and $33.52, with a volume of 1.20M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Alto Neuroscience Inc. (ANRO) moved from $23.30 to $30.60, representing a gain of 31.32% ($7.30).
The stock traded between $21.83 and $33.52 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 761.32 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 74.2%
ANRO is currently trading at $30.60, placing it 74.2% of the way from its 52-week low of $10.80 to its 52-week high of $37.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 68 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for Alto Neuroscience Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Alto Neuroscience Inc. (ANRO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ANRO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ANRO shares and USD.
ANRO Shares to USD
1.00 ANRO shares = 30.597 USD
Calculations are estimates based on the latest available price and are for reference only.